Evidence map›Paper›PMID 29970012›Full record

ArticleBMC infectious diseases2018

Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum.

Nicholas D Walter, Camille M Moore, Xavier A Kayigire, Christian Dide-Agossou, William Worodria, Laurence Huang, Charles K Everett, Gary S Schoolnik, Payam Nahid, J Lucian Davis

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  3. Article
  4. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and theirFrontiers in cellular and infection microbiology · 2022
    Review
  5. Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.American journal of respiratory and critical care medicine · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Nicholas D WalterPulmonary Section, Denver VA Medical Center, Denver, CO, USA. nicholas.walter@ucdenver.edu.ORCID 0000-0003-0126-1993
Camille M MooreDivision of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, USA.
Xavier A KayigireDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO, USA.
Christian Dide-AgossouDepartment of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.
William WorodriaInfectious Disease Research Collaboration, Kampala, Uganda.
Laurence HuangDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
Charles K EverettDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
Gary S SchoolnikDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Payam NahidDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
J Lucian DavisYale School of Public Health, New Haven, CT, USA.
San Francisco General Hospital · USColorado School of Public Health · USDenver VA Medical Center · USMulago Hospital · UGNational Jewish Health · USStanford University · USUniversity of Colorado Denver · USYale University · US

Funding

Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study - Diversity SupplementR01HL128156 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LAURENCE, HUNT, PETER W · 2015 to 2024
$7.1M
International HIV-associated Opportunistic Pneumonias (IHOP) StudyR01HL090335 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LAURENCE · 2007 to 2011
$4.0M
Patient-Oriented Research and Mentoring in PneumocystisK24HL087713 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LAURENCE · 2006 to 2018
$1.8M
Oral Wash for Nucleic Acid Diagnosis and Prognosis of TB in HIV-Infected UgandansK23AI080147 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DAVIS, JOHN LUCIAN · 2008 to 2012
$711k
Blood Expression Profiles as a Biomarker for Responses to Tuberculosis TreatmentIK2CX000914 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI WALTER, NICHOLAS D · 2014 to 2018
–
CSRD VA IK2 CX000914Doris Duke Charitable Foundation (US) 2017077NHLBI NIH HHS K24 HL087713NHLBI NIH HHS R01 HL090335NIAID NIH HHS K23 AI080147NIH HHS K23AI080147NIH HHS K24HL087713NIH HHS R01HL090335U.S. Department of Veterans Affairs CDA1IK2CX000914-01A1
6 · The paper itself

Abstract

backgroundAccording to the traditional tuberculosis (TB) treatment paradigm, the initial doses of treatment rapidly kill most Mycobacterium tuberculosis (Mtb) bacilli in sputum, yet many more months of daily treatment are required to eliminate a small, residual subpopulation of drug-tolerant bacilli. This paradigm has recently been challenged following the discovery that up to 90% of Mtb bacilli in sputum are culturable only with growth-factor supplementation. These "differentially culturable" bacilli are hypothesized to be more drug-tolerant than routinely culturable bacilli. This hypothesis implies an alternative paradigm in which TB treatment does not rapidly reduce the total Mtb population but only the small, routinely culturable subpopulation. To evaluate these competing paradigms, we developed a culture-independent method for quantifying the viable fraction of Mtb bacilli in sputum during treatment.

methodsWe used GeneXpert MTB/RIF to quantify Mtb DNA in sputa collected longitudinally from Ugandan adults taking standard 4-drug treatment for drug-susceptible pulmonary TB. We modeled GeneXpert cycle thresholds over time using nonlinear mixed-effects regression. We adjusted these models for clearance of DNA from killed-but-not-yet-degraded bacilli, assuming clearance half-lives ranging from 0 to 1.25 days. We used a convolution integral to quantify DNA from viable bacilli only, and converted cycle thresholds to Mtb genomic equivalents. We replicated our results in a South African cohort.

resultsWe enrolled 41 TB patients in Uganda. Assuming a DNA-clearance half-life of 0 days, genomic equivalents of viable sputum bacilli decreased by 0.22 log/day until 8.8 days, then by 0.07 log/day afterwards. Assuming a DNA-clearance half-life of 1.25 days, genomic equivalents of viable bacilli decreased by 0.36 log/day until 5.0 days, then by 0.06 log/day afterwards. By day 7, viable Mtb had decreased by 97.2-98.8%. We found similar results for 19 TB patients in South Africa. DISCUSSION: Using a culture-independent method, we found that TB treatment rapidly eliminates most viable Mtb in sputum. These findings are incompatible with the hypothesis that differentially culturable bacilli are drug-tolerant.

conclusionsA culture-independent method for measuring viable Mtb in sputum during treatment corroborates the traditional TB treatment paradigm in which a rapid bactericidal phase precedes slow, elimination of a small, residual bacillary subpopulation.

Indexed as

AdultDNA, ViralDrug Resistance, MicrobialFemaleHumansMaleMycobacterium tuberculosisSouth AfricaSputumTuberculosis, PulmonaryUgandaDNA, ViralDifferentially culturableDrug toleranceMycobacterium tuberculosisSputumTreatmentTuberculosis

Identifiers

PMID29970012
PMCPMC6029172
OpenAlexW2809711393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.